sorafenib has been researched along with Complication, Postoperative in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X; Shi, D; Wang, F; Wang, J; Zhang, J | 1 |
| Huang, X; Li, G; Li, W; Mu, X; Qian, X; Qin, J; Sun, B; Tan, S; Tan, Z; Wang, X; Xu, X; Zhang, W; Zhu, Z | 1 |
| Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS | 1 |
| Barbier, L; Belghiti, J; Faivre, S; Fuks, D; Le Treut, YP; Muscari, F; Pessaux, P | 1 |
| Ganten, TM; Hoffmann, K; Koschny, R; Mehrabi, A; Pfeiffenberger, J; Radeleff, B; Schemmer, P; Schmitz, A; Stremmel, W | 1 |
| Ekser, B; Fridell, JA; Klingler, KR; Kubal, CA; Maluccio, MA; Mangus, RS; Nagai, S; Tector, AJ | 1 |
| Campbell, SC; Fergany, A; Garcia, JA; Gill, IS; Klein, EA; Krishnamurthi, V; Novick, AC; Rini, BI; Stephenson, AJ; Thomas, AA; Zhou, M | 1 |
| Bose, D; Ellis, LM; Flaherty, KT; Hofstetter, W; Meric-Bernstam, F; Reardon, DA | 1 |
| Allen, GI; Chung, BI; Gill, HS; Harshman, LC; Srinivas, S; Yu, RJ | 1 |
| Abou-Alfa, GK; Gish, RG; Tong, MJ | 1 |
| Easson, AM; Eng, FC; Knox, JJ; Szentgyorgyi, E | 1 |
| Jonasch, E; Margulis, V; Matin, SF; Swanson, DA; Tamboli, P; Tannir, N; Wood, CG | 1 |
1 review(s) available for sorafenib and Complication, Postoperative
| Article | Year |
|---|---|
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Chemotherapy, Adjuvant; Humans; Indoles; Neoadjuvant Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2010 |
11 other study(ies) available for sorafenib and Complication, Postoperative
| Article | Year |
|---|---|
Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Neoplasm Invasiveness; Portal Vein; Postoperative Complications; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Venous Thrombosis | 2021 |
Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor: Analysis of a preliminary experience on 15 consecutive cases.
Topics: Adult; Aged; Antineoplastic Agents; Blood Vessel Prosthesis; End Stage Liver Disease; Female; Hepatectomy; Hepatic Veins; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Complications; Sorafenib; Treatment Outcome; Young Adult | 2017 |
Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hematologic Neoplasms; Hepacivirus; Hepatectomy; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Patient Selection; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Serologic Tests; Sorafenib; Survival Rate; Young Adult | 2017 |
Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Carcinoma, Hepatocellular; Case-Control Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Postoperative Complications; Prognosis; Sorafenib; Survival Rate; Young Adult | 2013 |
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Complications; Retrospective Studies; Sirolimus; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combined Modality Therapy; Follow-Up Studies; Graft Survival; Humans; Liver Neoplasms; Liver Transplantation; Lymphocytes; Multivariate Analysis; Neoplasm Recurrence, Local; Neutrophils; Niacinamide; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Survival Rate | 2015 |
Surgical resection of renal cell carcinoma after targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2009 |
Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Urinary Bladder | 2013 |
Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
Topics: Ablation Techniques; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Risk Factors; Sorafenib | 2010 |
Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Colonic Diseases; Colonoscopy; Diagnosis, Differential; Follow-Up Studies; Humans; Intestinal Perforation; Kidney Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Receptors, Vascular Endothelial Growth Factor; Rupture, Spontaneous; Sorafenib; Tomography, X-Ray Computed | 2009 |
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |